Background: Supercharged GFP proteins were known as effective carriers for delivery
of macromolecules into eukaryotic cells as well as fluorescent fusion tags for in vitro and in vivo
Objective: Herein, anti-viral effects of +36 GFP and its anti-tumor effects were studied in vitro and
in vivo, respectively.
Methods: We evaluated anti-HIV, anti-HSV, and anti-HCV effects of +36 GFP in vitro using
ELISA, and real time PCR as common techniques for their detection, respectively. Moreover, we
assessed the role of +36 GFP for eliciting HPV-related anti-tumor effects in mice due to the lack of
HPV replication in vitro.
Results: Our data showed that +36 GFP efficiently enter the cells and augment the transfection rate
of HPV16E7 antigen, as well. Furthermore, +36 GFP significantly reduced HCV, HIV and HSV
replication up to 75%, 49% and 43% in HCV-infected Huh7.5 cells, HIV-infected Hela cells and
HSV-infected Vero cells, respectively. On the other hand, mice immunization with +36 GFP
complexed with HPV16 E7 antigen (+36GFP + E7) or fused to HPV16 E7 antigen (+36GFP-E7)
elicited a higher Th1 cellular immune response with the predominant IgG2a, IgG2b, IFN-γ and
Granzyme B levels than those induced by other groups. These regimens protected mice against TC-
1 tumor challenge (~ 67%) compared to E7 protein alone (~ 33%). These data suggested that +36
GFP can act as an anti-viral agent at certain dose due to its high efficiency in cell penetration in
vitro and in vivo.
Conclusion: Generally, +36 GFP targets viral replication in vitro as well as helps to suppress the
growth of HPV-related tumors in vivo.